CA
ALDX icon

Clearstead Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Clearstead Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,007
Closed -$51.8K – 2263
2025
Q4 		$51.8K Sell
10,007
-501
-5% -$2.57K ﹤0.01% 1392
2025
Q3 		$54.9K Buy
10,508
+450
+4% +$2.35K ﹤0.01% 1254
2025
Q2 		$38.5K Sell
10,058
-340
-3% -$879 ﹤0.01% 1376
2025
Q1 		$59.8K Hold
10,398
– – ﹤0.01% 1129
2024
Q4 		$51.9K Hold
10,398
– – ﹤0.01% 1152
2024
Q3 		$56K Hold
10,398
– – ﹤0.01% 1179
2024
Q2 		$34.4K Buy
+10,398
New +$40.7K ﹤0.01% 1254

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clearstead Advisors's ALDX Position: Q1 2026 in Review

Clearstead Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 10,007 shares — an estimated $51.8K sold.

Clearstead Advisors first reported a position in ALDX in Q2 2024 and held it in 7 quarters. The position peaked at $59.8K in Q1 2025. 128 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Clearstead Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clearstead Advisors sold 10,007 Aldeyra Therapeutics shares in Q1 2026, an estimated $51.8K.
  • Clearstead Advisors first reported a position in Aldeyra Therapeutics in Q2 2024 and held it in 7 quarters.
  • Clearstead Advisors's Aldeyra Therapeutics position peaked at $59.8K in Q1 2025.
  • 128 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.